Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.
暂无分享,去创建一个
Peter J Houghton | John M Maris | Richard Gorlick | S. Keir | J. Maris | P. Houghton | R. Lock | Malcolm A. Smith | R. Gorlick | Min H. Kang | I. Dvorchik | Malcolm A Smith | Stephen T Keir | Igor Dvorchik | Jianrong Wu | C. Billups | E Anders Kolb | C Patrick Reynolds | Jianrong Wu | Catherine A Billups | R. Kurmasheva | C. Reynolds | E. Kolb | Brendan Murphy | Han Yin | Min H Kang | Raushan T Kurmasheva | Nana Boateng | Richard B Lock | B. Murphy | Malcolm A. Smith | Han Yin | N. Boateng | Peter J. Houghton | E. A. Kolb
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] J. Khan,et al. Molecular Characterization of the Pediatric Preclinical Testing Panel , 2008, Clinical Cancer Research.
[3] E. Sausville,et al. Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.
[4] Peter J Houghton,et al. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[5] S. Keir,et al. Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program , 2014, Clinical Cancer Research.
[6] X. Wang,et al. Emerging Insights into the Ependymoma Epigenome , 2013, Brain pathology.
[7] A. Goldin,et al. Progress report on the screening program at the Division of Cancer Treatment, National Cancer Institute. , 1980, Cancer treatment reviews.
[8] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[9] Peter J Houghton,et al. Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.
[10] A. Goldin,et al. The new NCI screen and its implications for clinical evaluation. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[11] C. Mullighan. Genomic characterization of childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.
[12] P. Meltzer,et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response , 2014, Genes & development.
[13] David T. W. Jones,et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.
[14] R. Lock,et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. , 2004, Blood.
[15] S. Keir,et al. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673 , 2015, Pediatric blood & cancer.
[16] S. Keir,et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.
[17] F. Speleman,et al. Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. M. Cobb,et al. The growth kinetics of xenografts of human colorectal tumours in immune deprived mice. , 1975, British Journal of Cancer.
[19] P. Houghton,et al. Growth and characterization of childhood rhabdomyosarcomas as xenografts. , 1982, Journal of the National Cancer Institute.
[20] N. Cheung,et al. Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era , 2014, Cancer.
[21] M. Junttila,et al. Translational value of mouse models in oncology drug development , 2015, Nature Medicine.
[22] S. Keir,et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.
[23] I. Yang,et al. Genetic expression profiles of adult and pediatric ependymomas: Molecular pathways, prognostic indicators, and therapeutic targets , 2013, Clinical Neurology and Neurosurgery.
[24] S. Keir,et al. Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.
[25] L. Staudt,et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. , 2009, The Journal of clinical investigation.
[26] P. Houghton,et al. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. , 2004, European journal of cancer.
[27] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[28] Volker Hovestadt,et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.
[29] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[30] S. Keir,et al. Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[31] D. Taylor,et al. Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice. , 1978, British Journal of Cancer.
[32] Joseph Zeidner,et al. The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.
[33] L. Muhlbaier,et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. , 1988, Cancer Research.
[34] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[35] P. Meltzer,et al. Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma , 2014, Clinical Cancer Research.
[36] Samuel A. Williams,et al. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century , 2013, Laboratory Investigation.
[37] A. Goldin,et al. A prospective screening program: current screening and its status. , 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[38] G. Getz,et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.
[39] S. Keir,et al. Initial testing of dasatinib by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.
[40] P. Houghton,et al. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. , 2015, Blood.
[41] R. Brenner,et al. Phenotypic instability of Saos-2 cells in long-term culture. , 2005, Biochemical and biophysical research communications.
[42] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[43] Peter Houghton,et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. , 2007, Cancer research.
[44] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[45] Jean-Pierre Gillet,et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.
[46] F. Barr,et al. Classification of Rhabdomyosarcoma and Its Molecular Basis , 2013, Advances in Anatomic Pathology.
[47] P. Houghton,et al. Preclinical Chemotherapeutic Tumor Models of Common Childhood Cancers: Solid Tumors, Acute Lymphoblastic Leukemia, and Disseminated Neuroblastoma , 2007, Current protocols in pharmacology.